🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Resveratrol prevents arsenic-induced depression-like phenotypes via modulation of BDNF signaling.

PMID: 41380913 · DOI: 10.1016/j.bbr.2025.115988 · Behavioural brain research, 2026 · Mohaddeseh Kharazmi, Tayyebeh Khalili, Marzieh Dehghan-Shasaltaneh, Abbas Bahari, Mohaddeseh Ebrahimi-Ghiri
📄 Abstract

Growing evidence suggests that resveratrol possesses neuroprotective properties against arsenic toxicity. This study investigated whether resveratrol could ameliorate arsenic-induced depression-like behaviors in male Naval Medical Research Institute (NMRI) mice and explored potential molecular mechanisms. Mice were exposed to arsenic (50 mg/L in drinking water) for 4 weeks and treated with resveratrol (10 or 20 mg/kg). Behavioral assessments included the hole-board test (HBT) for exploratory behavior, and the sucrose splash test (SST), tail suspension test (TST), and forced swim test (FST) for depression-like behaviors. The mRNA levels of Bdnf, Creb1, and Dvl1 in the brain were analyzed by qRT-PCR. Arsenic exposure induced significant depression-like behaviors, characterized by decreased grooming in SST and increased immobility in TST and FST. Resveratrol treatment prevented these behavioral alterations and exhibited intrinsic antidepressant effects in naïve mice, with dose-dependent reductions in immobility time (FST) and increased grooming (SST). Notably, resveratrol (20 mg/kg) enhanced rearing frequency in naïve mice and decreased it in the arsenic-treated mice. At the molecular level, arsenic downregulated Bdnf expression, while resveratrol restored its levels. In contrast, no significant changes in Creb1 and Dvl1 expression were observed. These findings indicate that resveratrol mitigates arsenic-induced depression-like behaviors primarily through the modulation of Bdnf-dependent pathways, independent of Creb1 and Dvl1. These results position resveratrol as a potential antidepressant and underscore its therapeutic promise for mood disorders associated with environmental toxicant exposure.

Confidence: 0.24 · 12 полей извлечено
Идентификация (6 полей)
Target
BDNF
0.95
Alt. target
Brain-derived neurotrophic factor
0.90
Protein family
Neurotrophin family
0.85
Functional class
Growth factor
0.80
Subcellular loc.
Secreted
0.70
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Mechanism
modulation of BDNF signaling
0.90
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
0.00
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
0.00
Cell death
0.00
Adipocyte fibrosis
0.00
Upstream (biochem)
0.00
Upstream (physiol)
0.00
Downstream (biochem)
0.00
Downstream (physiol)
0.00
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
brain
0.90
In vitro
0.00
In vivo
male Naval Medical Research Institute (NMRI) mice exposed to arsenic (50 mg/L in drinking water) for 4 weeks and treated with resveratrol (10 or 20 mg/kg)
1.00
In silico
0.00
Genetic association
0.00
Ex vivo
0.00
Animal model
male Naval Medical Research Institute (NMRI) mice
1.00
Diet/model
arsenic exposure (50 mg/L in drinking water) for 4 weeks
1.00
Клиника (11 полей)
Drug
Resveratrol
1.00
Indication
Depression-like behaviors associated with arsenic toxicity; potential antidepressant for mood disorders related to environmental toxicant exposure
0.90
Patient subgroups
0.00
Safety concerns
0.00
Off-target
0.00
Trial stage
0.00
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
0.00